JHSM
Journal of Health Sciences and Medicine

Journal of Health Sciences and Medicine (JHSM) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

ISSN: Active
eISSN: 2636-8579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Letter to the Editor
Advanced cervical cancer: how to interpret the new standard of care
Abstract
As pivotal practice-changing studies, the KEYNOTE-826 (KN826) and BEATcc trials provided the opportunity to add immune checkpoint inhibitors (ICPIs) to the combination of platinum-taxane doublet chemotherapy and bevacizumab, which has been the standard of care for advanced cervical cancer for many years. Combination with ICPI represents the current benchmark for the first-line treatment of advanced cervical cancer. However, there are still issues that need to be questioned in terms of precision medicine. Studies that are not limited by the selection criteria of randomized clinical trials, reflect real-life practices, and measure outcomes for larger patient groups with more balanced representation of different subgroups would be valuable.

Keywords : Metastatic cervical cancer, immunotherapy, patient subgroups

Download Article


1. Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734-743. doi:10.1056/NEJMoa1309748
2. Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856-1867. doi:10.1056/NEJMoa2112435
3. Oaknin A, Gladieff L, Martínez-García J, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. Lancet. 2024;403(10421):31-43. doi:10.1016/S0140-6736(23)02405-4
4. Luo PH, Mo DC, Wang HL, Liang XJ, Huang JF. Predicted value of PD-L1 for patients with cervical cancer treated with pembrolizumab. J Clin Oncol. 2024;42(13):1596. doi:10.1200/JCO.23.02479
5. Lichter KE, Levinson K, Hammer A, Lippitt MH, Rositch AF. Understanding cervical cancer after the age of routine screening: characteristics of cases, treatment, and survival in the United States. Gynecol Oncol. 2022;165(1):67-74. doi:10.1016/j.ygyno.2022.01.017
Article available in :
Volume 8, Issue 3, 2025
Page : 535-535
https://doi.org/10.32322/jhsm.1638213
Article Information
Received : 12 Şub 2025
Accepted : 20 Nis 2025
Published : 30 May 2025
Corresponding Author :

Seda Kahraman: Department of Medical Oncology, Gülhane Training and Research Hospital, University of Health Sciences, Ankara, Turkiye

[email protected]
Citation : Kahraman S, Atacan H. Advanced cervical cancer: how to interpret the new standard of care. J Health Sci Med. 2025;8(3):535.

Read: 6
Cited: 0
Download : 13
_Footer